scholarly journals The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030

2021 ◽  
Vol 15 (7) ◽  
pp. e0009604
Author(s):  
Natalie V. S. Vinkeles Melchers ◽  
Wilma A. Stolk ◽  
Welmoed van Loon ◽  
Belén Pedrique ◽  
Roel Bakker ◽  
...  
Keyword(s):  
Total Population ◽  
Vision Loss ◽  
New Drugs ◽  
Eye Disease ◽  
River Blindness ◽  
Control Distribution ◽  
Disability Weights ◽  
Life Years ◽  
Disease Study ◽  
Onchocerciasis Control

Background Onchocerciasis (“river blindness”) can cause severe morbidity, including vision loss and various skin manifestations, and is targeted for elimination using ivermectin mass drug administration (MDA). We calculated the number of people with Onchocerca volvulus infection and onchocercal skin and eye disease as well as disability-adjusted life years (DALYs) lost from 1990 through to 2030 in areas formerly covered by the African Programme for Onchocerciasis Control. Methods Per MDA implementation unit, we collated data on the pre-control distribution of microfilariae (mf) prevalence and the history of control. Next, we predicted trends in infection and morbidity over time using the ONCHOSIM simulation model. DALY estimates were calculated using disability weights from the Global Burden of Disease Study. Results In 1990, prior to MDA implementation, the total population at risk was 79.8 million with 26.0 million (32.5%) mf-positive individuals, of whom 17.5 million (21.9%) had some form of onchocercal skin or eye disease (2.5 million DALYs lost). By 2030, the total population was predicted to increase to 236.1 million, while the number of mf-positive cases (about 6.8 million, 2.9%), people with skin or eye morbidity (4.2 million, 1.8%), and DALYs lost (0.7 million) were predicted to decline. Conclusions MDA has had a remarkable impact on the onchocerciasis burden in countries previously under the APOC mandate. In the few countries where we predict continued transmission between now and 2030, intensified MDA could be combined with local vector control efforts, or the introduction of new drugs for mopping up residual cases of infection and morbidity.

scholarly journals Slaying little dragons: the impact of the Guinea Worm Eradication Program on dracunculiasis disability averted from 1990 to 2016

2018 ◽  
Vol 2 ◽  
pp. 30 ◽  
Author(s):  
Elizabeth A. Cromwell ◽  
Sharon Roy ◽  
Dieudonne P. Sankara ◽  
Adam Weiss ◽  
Jeffrey Stanaway ◽  
...  
Keyword(s):  
Clinical Symptoms ◽  
Case Reports ◽  
Annual Number ◽  
Infection Prevalence ◽  
Eradication Program ◽  
Guinea Worm ◽  
Disability Weights ◽  
Life Years ◽  
Disease Study ◽  
The Impact

Background:The objective of this study was to document the worldwide decline of dracunculiasis (Guinea worm disease, GWD) burden, expressed as disability-adjusted life years (DALYs), from 1990 to 2016, as estimated in the Global Burden of Disease study 2016 (GBD 2016). While the annual number of cases of GWD have been consistently reported by WHO since the 1990s, the burden of disability due to GWD has not previously been quantified in GBD.Methods:The incidence of GWD was modeled for each endemic country using annual national case reports. A literature search was conducted to characterize the presentation of GWD, translate the clinical symptoms into health sequelae, and then assign an average duration to the infection. Prevalence measures by sequelae were multiplied by disability weights to estimate DALYs.Results:The total DALYs attributed to GWD across all endemic countries (n=21) in 1990 was 50,725 (95% UI: 35,265–69,197) and decreased to 0.9 (95% UI: 0.5–1.4) in 2016. A cumulative total of 12,900 DALYs were attributable to GWD from 1990 to 2016.Conclusions:Using 1990 estimates of burden propagated forward, this analysis suggests that between 990,000 to 1.9 million DALYs have been averted as a result of the eradication program over the past 27 years.

Time trends, associations and global burden of intraocular foreign bodies

2020 ◽  
pp. bjophthalmol-2020-317063
Author(s):  
Guangming Jin ◽  
Minjie Zou ◽  
Yichi Zhang ◽  
Aiming Chen ◽  
Charlotte Aimee Young ◽  
...  
Keyword(s):  
Time Trends ◽  
Disease Burden ◽  
Foreign Bodies ◽  
Vision Loss ◽  
Global Burden ◽  
Country Level ◽  
Level Data ◽  
Disability Adjusted Life ◽  
Life Years ◽  
Disease Study

PurposeTo estimate the disease burden due to intraocular foreign bodies (IOFBs) and evaluate contributions of various risk factors to IOFB-associated disability-adjusted life-years (DALYs).MethodsGlobal, regional and country-level number, rate and age-standardised rate of DALYs due to IOFBs were acquired from the Global Burden of Disease Study 2017 database. The Human Development Index (HDI) and other region and country-level data were obtained from open databases. Time trends for number, rate and age-standardised rate of DALYs due to IOFBs were calculated. Regression analysis was used to evaluate associations between age-standardised rate of DALYs and potential predictors.ResultsGlobal DALYs due to IOFBs rose by 43.7% between 1990 (139 (95% CI 70.8 to 233) thousand) and 2017 (202 (95% CI 105 to 335) thousand). The DALY rate remained stable while the age-standardised rate decreased during this period. Higher disease burden due to IOFBs was associated with higher glaucoma prevalence (β=0.006, 95% CI 0.003 to 0.09, p<0.001), lower refractive error prevalence (β=−0.0005, 95% CI −0.0007 to −0.0002, p<0.001), and lower income (β=−0.020, 95% CI −0.035 to −0.006, p=0.007).ConclusionPredictors of a greater burden of IOFB disability generally point to lower socioeconomic level. The association with glaucoma may reflect a complication of IOFB, increasing risk of vision loss and disability.

Burden of near vision loss in China: findings from the Global Burden of Disease Study 2019

2021 ◽  
pp. bjophthalmol-2021-319603
Author(s):  
Guangming Jin ◽  
Minjie Zou ◽  
Chi Liu ◽  
Aiming Chen ◽  
Yi Sun ◽  
...  
Keyword(s):  
Burden Of Disease ◽  
Vision Loss ◽  
Developed Countries ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Near Vision ◽  
Disability Adjusted Life ◽  
Life Years ◽  
And Gender ◽  
Disease Study

PurposeTo investigate the burden of near vision loss (NVL) in China by year, age and gender from 1990 to 2019.MethodsWe used estimates from the Global Burden of Disease (GBD) 2019 study to report the prevalence and disability-adjusted life-years (DALYs) due to NVL in China. Estimates of crude counts and age-standardised rates per 100 000 population are accompanied by 95% uncertainty intervals (UIs). We summarised the age-specific and sex-specific patterns and trends regarding the burden of NVL in China, compared with seven neighbouring countries.ResultsFrom 1990 to 2019, the all-age number and rate for NVL prevalence and DALYs increased significantly in China (all p<0.001). The age-standardised rate decreased from 7538.1 (95% UI 6946.3 to 8075.1) to 7392.9 (95% UI 6855.8 to 7890.5) per 100 000 population for NVL prevalence (p=0.107), and from 74.9 (95% UI 69.6 to 79.9) to 73.8 (95% UI 70.6 to 80.1) per 100 000 population for DALYs (p=0.388). Women had higher NVL prevalence (t=170.1, p<0.001) and DALYs (t=192.5, p<0.001) than men. Higher disease burden of NVL was observed in the middle-aged and elderly population. The age-standardised prevalence and DALY rate attributable to NVL in China were lower than in India, North Korea, Pakistan (all p<0.001), but higher than Russia, South Korea, Singapore and Japan (all p<0.001).ConclusionsDespite a small decrease in age-standardised prevalence and DALYs due to NVL in China in the past two decades, the existing burden is still considerable and significantly higher compared with neighbouring developed countries. An approach that includes all stakeholders is needed to further reduce this burden.

scholarly journals Burden of vision loss associated with eye disease in China 1990–2020: findings from the Global Burden of Disease Study 2015

2017 ◽  
Vol 102 (2) ◽  
pp. 220-224 ◽  
Author(s):  
Bingsong Wang ◽  
Nathan Congdon ◽  
Rupert Bourne ◽  
Yichong Li ◽  
Kai Cao ◽  
...  
Keyword(s):  
Vision Loss ◽  
Eye Diseases ◽  
Eye Disease ◽  
Global Burden ◽  
International Forum ◽  
Health Loss ◽  
Global Burden Of Diseases ◽  
Disease Study ◽  
Years Lived With Disability ◽  
Burden Of Diseases

AimsTo assess the burden of vision loss due to eye disease in China between 1990 and 2015, and to predict the burden in 2020.MethodsData from the GBD 2015 (Global Burden of Diseases, Injuries, and Risk Factors Study 2015) were used. The main outcome measures were prevalence and years lived with disability (YLDs) for vision loss due to cataract, glaucoma, macular degeneration, other vision loss, refraction and accommodation disorders and trachoma.ResultsPrevalence for eye diseases increased steadily from 1990 to 2015, and will increase until 2020. From 1990 to 2015, the most common eye disorder was refraction and accommodation disorders. From 1990 to 2015, the vision loss burden due to eye disease decreased for those aged 0–14 years, and increased for those aged 15 years and above, with the most notable increases occurring among those aged 50 years and above. China ranked 10th when comparing YLDs for vision loss due to eye disease with the other members of the G20 (Group of Twenty, an international forum for the governments from 20 major economies) . Age-standardised YLD rates for vision loss due to eye disease declined in all 19 countries, except for China. The burden from vision loss due to eye disease ranked 12th and 11th among all causes of health loss in China in 1990 and 2015, respectively.ConclusionAlone among major economies, China has experienced an increase in the burden of age-standardised vision loss from eye disease over the last two decades. In the future, China may expect a growing burden of vision loss due to population growth and ageing.

scholarly journals Changes in Lens Opacities on the Age-Related Eye Disease Study Grading Scale Predict Progression to Cataract Surgery and Vision Loss

Ophthalmology ◽  
2015 ◽  
Vol 122 (5) ◽  
pp. 888-896 ◽  
Author(s):  
Maanasa Indaram ◽  
Elvira Agrón ◽  
Traci E. Clemons ◽  
Robert D. Sperduto ◽  
Wai T. Wong ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Vision Loss ◽  
Eye Disease ◽  
Age Related ◽  
Grading Scale ◽  
Lens Opacities ◽  
Disease Study

scholarly journals How do Japanese rate the severity of different diseases and injuries?—an assessment of disability weights for 231 health states by 37,318 Japanese respondents

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Shuhei Nomura ◽  
Yoshiko Yamamoto ◽  
Daisuke Yoneoka ◽  
Juanita A. Haagsma ◽  
Joshua A. Salomon ◽  
...  
Keyword(s):  
Japanese Population ◽  
Vision Loss ◽  
Paired Comparison ◽  
Probit Regression ◽  
Health States ◽  
Uncertainty Interval ◽  
Mild Anemia ◽  
Disability Weights ◽  
Life Years ◽  
Cord Injury

Abstract Background Disability weights (DWs) are weight factors that reflect the severity of health states for estimates of disability-adjusted life years. A new set of global DWs was published for the Global Burden of Diseases and Injuries (GBD) 2013 study, which relied on sampling from various world regions, but included little data for countries in East Asia. This study aimed to measure DWs in Japan using comparable methods, and compare the results with previous estimates from the GBD 2013 DW study. Methods We conducted a web-based survey in 2019 to estimate DWs for 231 health states for the Japanese population. The survey included five new health states but otherwise followed the method of the GBD DW measurement study. The survey consisted of 15 paired comparison (PC) questions and 3 population health equivalence questions (PHE) per respondent. We analyzed PC data using probit regression and rescaled results to DW units between 0 (equivalent to full health) and 1 (equivalent to death). Findings We considered 37,318 nationally representative respondents. The values of the resulting DWs ranged from 0.707 (95% uncertainty interval (UI) 0.527–0.842) for spinal cord injury at neck level (untreated) to 0.004 (UI 0.001–0.009) for mild anemia. High correlation between Japanese DW and GBD 2013 DW was observed, but there was considerable disagreement. Out of 226 comparable health states, 55 (24.3%) showed more than a factor-of-two difference, of which 41 (74.6%) had a higher value in Japanese DW. Many of the health states with higher DW in the Japan study were injuries, including amputation and fracture, and hearing and vision loss, while mental, behavioral, and substance use disorders generally tended to be lower. Conclusions This study has created an empirical basis for assessment of Japanese DWs of health status. The findings from this study based on the Japanese population suggest that there might be contextual differences in rating the severity of health states compared to previous surveys conducted elsewhere.

scholarly journals Rho-Kinase Inhibitors for the Treatment of Refractory Diabetic Macular Oedema

Cells ◽  
2021 ◽  
Vol 10 (7) ◽  
pp. 1683
Author(s):  
Milagros Mateos-Olivares ◽  
Luis García-Onrubia ◽  
Fco. Javier Valentín-Bravo ◽  
Rogelio González-Sarmiento ◽  
Maribel Lopez-Galvez ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Macular Oedema ◽  
Standard Therapy ◽  
Vision Loss ◽  
Therapeutic Potential ◽  
Rho Kinase ◽  
Diabetic Macular Oedema ◽  
New Drugs ◽  
Anti Vegf

Diabetic macular oedema (DMO) is one of the leading causes of vision loss associated with diabetic retinopathy (DR). New insights in managing this condition have changed the paradigm in its treatment, with intravitreal injections of antivascular endothelial growth factor (anti-VEGF) having become the standard therapy for DMO worldwide. However, there is no single standard therapy for all patients DMO refractory to anti-VEGF treatment; thus, further investigation is still needed. The key obstacles in developing suitable therapeutics for refractory DMO lie in its complex pathophysiology; therefore, there is an opportunity for further improvements in the progress and applications of new drugs. Previous studies have indicated that Rho-associated kinase (Rho-kinase/ROCK) is an essential molecule in the pathogenesis of DMO. This is why the Rho/ROCK signalling pathway has been proposed as a possible target for new treatments. The present review focuses on the recent progress on the possible role of ROCK and its therapeutic potential in DMO. A systematic literature search was performed, covering the years 1991 to 2021, using the following keywords: “rho-Associated Kinas-es”, “Diabetic Retinopathy”, “Macular Edema”, “Ripasudil”, “Fasudil” and “Netarsudil”. Better insight into the pathological role of Rho-kinase/ROCK may lead to the development of new strategies for refractory DMO treatment and prevention.

Sign in / Sign up

Export Citation Format

Share Document